Niraparib, rucaparib, olaparib, and talazoparib are PARP inhibitor drugs approved for certain breast/ovarian cancers associated with homologous recombination deficiency [[84], [85], [86], [87]]. This evidence concerns the gene PARP1 and ovarian cancer.